ClinicalTrials.gg
RecruitingNCT07558733Updated Jul 2, 2026

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

A Phase 1/2 interventional study of Serabelisib and Sapanisertib in HR+ HER2- Breast Cancer, sponsored by Faeth Therapeutics. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Faeth Therapeutics · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.

Read the detailed description

The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.

02

Conditions studied

  • HR+ HER2- Breast Cancer

Browse trials for

Keywords

  • Serabelisib
  • Sapanisertib
  • Fulvestrant
  • Palbociclib
  • PI3K
  • mTOR
  • Dual PI3K/mTOR inhibition
  • Genetic Mutation
  • Faslodex
  • SERDs
  • Select Estrogen Receptor Degraders
  • CDK
  • CDK46
  • CDK4-6
  • HER2-
  • HER2 negative
  • HR+
  • HR positive
  • Hormone Receptor Positive
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Recurrent Breast Cancer
  • Breast Cancer
  • Cancer of the breast
  • Carcinoma of the breast
  • Neoplasms, Breast
  • Metabolism
  • Synthetic Lethality
  • Metabolism Programming
  • PIK3CA
  • Oral Medications
  • Antineoplastic agents
  • AKT
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

This study's planned enrollment of 32 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Faeth Therapeutics is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of HR+/- breast cancer.
  • Documented evidence of advanced or recurrent disease that is not amenable to surgery/radiation for curative intent.
  • Participant has received at least one prior systemic therapy.
  • At least 1 measurable or evaluable target lesion according to v1.1
  • (ECOG) performance status of ≤ 1 at Screening.
  • Non-pregnant, non-lactating females who are , surgically sterile or who agree to use effective methods.

Exclusion criteria

Exclusion Criteria:

  • Participants with triple-negative breast cancer.
  • Participants with central nervous system are not eligible, unless they have completed local therapy and have discontinued the use of for this indication for at least 4 weeks before starting treatment in this study.
  • Active (except for breast cancer, definitively treated in-situ carcinomas [e.g., breast, cervix, bladder], or basal or squamous cell carcinoma of the skin) within the past 24 months prior to treatment. Fully resected localized malignancies are eligible.
  • Gastric feeding tube (gastrostomy tube), gastrointestinal malabsorption, gastrointestinal anastomosis, bowel obstruction, or any other condition that might affect the absorption of study treatment.
  • Significant cardiovascular impairment.
  • Active, uncontrolled infection.
  • Concurrent participation in another therapeutic clinical trial.
  • Prior radiation therapy within 21 days prior to start of study treatment.
  • Participants who have received a prior PI3K, AKT, mTORC1/2, or dual PI3K/mTOR inhibitor.
  • Strong inhibitors, strong CYP1A2 inhibitors or CYP1A2 inducers, or CYP3A4 inducers within 7 days before the first dose of study intervention, or participants who require treatment with strong CYP3A4 inhibitors or inducers during the study.
  • Prolongation of to >480 ms.
  • Type 1 or Type 2 diabetes mellitus on insulin.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Cohort A1 - Sapanisertib and serabelisib (PIKTOR) with fulvestrant

    Subjects will receive doses of sapanisertib and serabelisib (PIKTOR) administered orally and fulvestrant administered intramuscularly.

    Drug: Serabelisib · Drug: Sapanisertib · Drug: Fulvestrant

  • Experimental
    Cohort A2 - Sapanisertib and serabelisib (PIKTOR) with fulvestrant

    Subjects will receive doses of sapanisertib and serabelisib (PIKTOR) at a higher dose than Cohort A1 administered orally and fulvestrant administered intramuscularly.

    Drug: Serabelisib · Drug: Sapanisertib · Drug: Fulvestrant

Interventions

  • Serabelisib is a selective, small molecule inhibitor of PI3Kα.

  • Sapanisertib is a small molecule inhibitor of the mammalian mTOR serine/threonine kinase.

  • Fulvestrant is a first-in-class SERD.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of drugs by assessment of adverse events (AEs) / serious adverse events (SAEs)

    Graded according to the National Cancer Institute (NCI CTCAE v5.0).

    Time frame: 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Defined as the proportion of participants from the Response-Evaluable population who have confirmed best overall response of either CR or PR according to RECIST v1.1 as confirmed by the Investigator.

    Time frame: Up to 2 years.

  2. Progression Free Survival (PFS)

    Defined as the time from first dose to the date of the first evidence of disease progression or death.

    Time frame: Up to 5 years.

  3. Progression Free Survival (PFS) at 6 months

    Defined as the progression free survival (PFS) rate at 6 months.

    Time frame: 6 months

  4. Overall Survival (OS)

    Defined as the time from first dose to the date of death due to any cause.

    Time frame: Up to 5 years.

  5. Clinical Benefit Rate (CBR)

    Defined as the percentage of participants from the All Treated population who achieve CR, PR, or SD.

    Time frame: Up to 5 years.

  6. Duration of Response (DoR)

    Defined for participants with a confirmed CR or PR as the time from response to the date of first evidence of disease progression or death.

    Time frame: Up to 5 years.

07

Study locations

7 of 7 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2029, 37 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 37 months is below that.

Counting every sponsor, half of 327 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 30, 2026
StartActual
Apr 22, 2026
Primary completionEst.
May 2029
CompletionEst.
May 2033
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07558733
Lead sponsor
Faeth Therapeutics
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Apr 22, 2026
Primary completion
May 2029 (estimated)
Completion
May 2033 (estimated)
Last update
Jul 2, 2026

Study contacts

Medical Monitor
Contact
clinicaltrials@faeththerapeutics.com
(708) 406-9282

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Serabelisib · Sapanisertib

Start the discussion